# OnCo record glecirasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/glecirasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "glecirasib" ;
  schema:name "Glecirasib"@en ;
  schema:description "Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel."@en ;
  schema:url <https://onco.cc/drugs/glecirasib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=JAB-21822> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral covalent KRAS G12C inhibitor" ;
  onco:approval "CN 2024: KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:companies <https://onco.cc/companies/jacobio-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct06416410/>, <https://onco.cc/trials/nct05194995/>, <https://onco.cc/trials/nct05288205/>, <https://onco.cc/trials/nct07164170/>, <https://onco.cc/trials/nct05276726/>, <https://onco.cc/trials/nct05009329/>, <https://onco.cc/trials/nct06008288/> .